Pappas Capital - Pappas Capital

Us2.ai Secures US$15M Series A To Improve Detection of Cardiovascular Disease

SINGAPORE, 14 APRIL 2022: Us2.ai, the Singapore-based medtech developers of FDA- cleared AI software that, for the first time ever, fully automates a complete echocardiography (heart ultrasound) report, today announced it has raised US$15 million in a series A round led by IHH Healthcare and Heal Partners, with participation from Pappas Capital and existing investors including Sequoia India, EDBI and Partech Ventures. The new funds will be used to drive Us2.ai’s ambitious growth targets for clinical implementation in the US, Europe and Asia, as well as the expansion of commercial activities with leading pharmaceutical companies, research labs, and imaging providers worldwide.

Us2.ai - 04/15/2022

Pappas Capital Strengthens Investment Team With Appointments Of Cookie Yu And Gilbert Kinsey To Principal

RESEARCH TRIANGLE PARK, N.C., Dec. 1, 2021 -- Pappas Capital, a leading investor in early-stage life science and technology companies, today announced the promotions of Cookie Yu, PhD, and Gilbert Kinsey, PhD, PharmD, to Principal. Their promotions further strengthen the Pappas Capital team in support of the firm's continued growth and expansion.

Pappas Capital - 12/01/2021

SAS and Pappas Capital partner to propel AgTech startups with analytics

CARY, N.C., Oct. 20, 2021 -- Two North Carolina companies, analytics leader SAS and venture investment firm Pappas Capital, are joining forces to help advance the state as a global leader in agricultural technology. The state's AgTech sector is ripe for continued growth and innovation, and technologies such as artificial intelligence, machine learning and analytics are driving innovation in digital agriculture. The collaboration between SAS and Pappas will allow select NC agriculture and food startups to gain guidance and executive leadership from Pappas and access to industry-leading analytics software, data science expertise and cloud services from SAS.

Pappas Capital - 10/20/2021

Pappas Capital Strengthens Specialized Fund Management Business With Appointment Of Karen LeVert As Venture Partner

RESEARCH TRIANGLE PARK, NC, Feb. 3, 2020 -- Pappas Capital, a leading investor in early-stage life sciences companies, has appointed Karen LeVert as Venture Partner to help lead the expansion of the firm's Specialized Fund Management business, with a focus on identifying attractive investment opportunities in agricultural and other related technologies. Ms. LeVert has a proven track record of progressing early stage technologies from university research labs to commercialization, and most recently co-founded two independent innovation labs, Southeast TechInventures, Inc. (STI) and Ag TechInventures, LLC (AgTI).

Pappas Capital - 02/03/2020

Alex Arfaei Joins Pappas Capital As Partner

RESEARCH TRIANGLE PARK, N.C., Sept. 11, 2019 -- Pappas Capital, a leading investor in early-stage life sciences companies, announced today that Alex Arfaei has joined the firm as a Partner of Pappas Ventures. In his role, Mr. Arfaei will be responsible for helping to identify and evaluate investment opportunities for the firm's venture capital business. Previously, Mr. Arfaei served as a Managing Director with BMO Capital Markets, where he was a senior equity research analyst covering major pharmaceutical and biotechnology companies.

Pappas Capital - 09/11/2019

Pappas Capital Expands Leadership Team With Appointments Of Kyle Rasbach To Managing Partner And Matthew Boyer To Chief Financial Officer

RESEARCH TRIANGLE PARK, NC, July 16, 2019 -- Pappas Capital, a leading investor in early-stage life sciences companies, today announced the promotion of Kyle Rasbach, PhD, PharmD to a Managing Partner of Pappas Ventures, the firm's venture capital business. In his new role, Dr. Rasbach will help to oversee Pappas Ventures and lead fundraising and investment efforts for its future venture funds. Pappas Capital also announced that Matthew Boyer has been named Chief Financial Officer, succeeding Ford Worthy who will continue with the firm as a Partner and Senior Advisor.

Pappas Capital - 07/16/2019

New Pappas Capital Fund Makes First Investment

Research Triangle Park, NC, May 24, 2017 – Pappas Capital, a life science venture capital firm, announced today that its new fund, Pappas Ventures V, recently invested in OrphoMed, a clinical stage company that is developing best-in-class therapies for treatment of inadequately-controlled gastrointestinal disorders. The investment in OrphoMed is the first investment by the new Pappas Ventures fund.

OrphoMed - 05/24/2017

Investor Login